Background: Experimental investigation of stroke, in particular the evaluation of therapeutic maneuvers, is difficult because even well-controlled experiments show considerable variability. Optimal use of resources requires efficient statistical analysis.
T
here is a divinity in odd numbers.
-Merry Wives of Windsor V, i, 2
Evaluation of prospective therapies for stroke is not easy. Stroke patients show tremendous variability, so tight experimental control is not readily achieved. Even in experimental animals it is difficult to get reproducible experimental conditions. Although it is important to try to reduce experimental variability, optimal efficiency requires the use of statistical methods for the analysis of results. While it is often possible to get a rough idea of what is going on with the use of simple but familiar tools like the / test, experimental efficiency (getting the most information out of a set of experimental results) generally is achieved by using an analysis tailored to the nature of the experimental results. In the case of experiments on stroke this can involve statistical techniques that are standard in other fields but relatively unknown to those involved in stroke studies. It is our purpose to describe one of these data analysis techniques that has wide applicability to many types of stroke studies and, at the same time, is relatively easy to use with the aid of a computer and appropriate software.
The analysis comes from the area of pharmacology dealing with bioassays. For those unfamiliar with the term, a bioassay is simply an assay that, as distinguished from chemical assays, uses the response of a biological system to measure something. Typically a bioassay is used in early exploratory studies of newly discovered biological activity. For example, if we were to find a pressor activity (i.e., an ability to raise arterial pressure) in some biological extract, we would like to characterize the active principle chemically. To do so requires con-centrating it. But how can we know if any given procedure concentrated the active principle if we do not know its structure and have no chemical measurement for it? The answer is to use a bioassay. For example, at various stages of attempted purification, we might look at the effect of extracts on the arterial pressure of a rat. Thus, if 0.01 ml of extract after some stage of purification raises arterial pressure 30 mm Hg while 0.1 ml had been required before that stage, then that purification brought about a 10-fold increase in concentration. A bioassay can be used to do more than measure the amount of an unknown substance; a bioassay can facilitate the measurement of complex effects of a known compound. We wish to emphasize this last feature.
One of us has been working with two animal models that show fairly consistent responses. In one model, the spinal cord of a rabbit is the site of the stroke. 1 While this might seem inappropriate as an analogy to clinical stroke, the advantage is that the spinal cord anatomy is much more suitable than that of many other parts of the central nervous system because the spinal cord is laid out in a linear fashion. The spinal cord is based on the same building blocks as the rest of the central nervous system. Interference with the blood supply of a segment of the cord can be assessed very simply by noting whether the animal can use its hind legs. This provides an unambiguous end point -a good start in any bioassay. In another assay, we inject small particles of controlled size, microspheres, into the carotid circulation of a rabbit so that they lodge in cerebral arterioles and induce local ischemia. 2 We then note whether the animal is alert and able to right itself or has a gross neurological deficit. This end point is also clear-cut.
The response in each of these assays is all or none. The animal is scored as either affected or not. In the spinal cord model we see paraplegia or an animal that can move. The score is of the form 0 (not paraplegic) or quantal as opposed to graded. The classical example of a quantal response is death. In an assay of toxicity a mouse will be either dead or alive as the result of a given dose of some compound. There is no range of responses in between. This contrasts with a graded response such as a rise in arterial pressure or a decrease in airway resistance that might occur with the injection of epinephrine. With these last responses a whole range of values may occur.
When the results of quantal and graded assays are plotted there is a major difference in form. In Figure 1 we show what the characteristic plots look like. The graded curve on the right has the familiar shape that fits the usual dose-response curve, a sigmoid curve. The quantal curve on the left is quite different. All responses are either maximal or zero; no intermediate values appear. This major distinction means we view the two classes of response differently. When the underlying relation of response to dose is considered, the quantal response curve is more difficult to understand. Our goal is to spell out how the pharmacologist views quantal assay dose-response curves and, in particular, how to derive an ED50* or, more generally, to compare two curves to see the effect of a drug relative to a control system. In each case we show how a standard pharmacological procedure can be applied naturally to studies of the effects of drugs on stroke.
Underlying Nature of Quantal Dose-Response Curve When a graded dose-response relation such as that in the right panel of Figure 1 is viewed, it is easy to picture an associated curve that summarizes the underlying relation of effect to dose. It is possible to fit some function to the points and graph the results to get a smooth curve running through the middle of the points (we are intentionally vague here since the specifics are not of interest in the current context). The observed responses will generally not all lie on the line but will be scattered above and below it, presumably because of random errors of measurement, noise in the assay, or what-have-you. The observed points reflect an underlying relation somewhat obscured by some random, uncontrolled, superimposed error. Indeed, it is easy to imagine a perfect assay without error and in which the points all lie right on the line. ' The EDJO is defined as the dose that produces a half-maximal effect if the response is graded or produces an effect in 50% of the population if the response is quantal. The ED50 measures potency. The lower the EDso, the more potent the drug. The term LD50 is used in the special case when the effect is death (L as in lethal).
In the case of the quantal curve we again picture an underlying functional relation (typically sigmoid) between response and dose, but the points deviate from the line not because of error but because of an underlying probabilistic nature of the assay. This feature leads to a fundamental difference between the graded and quantal assays. In the quantal assay, even if there is complete precision in the measurements, the points will never lie on the line describing the underlying relation between dose and response. This means that this underlying relation seems more abstract than in the case of a graded curve. In fact it is not. We shall now spell things out more explicitly.
On the left side of Figure 1 , low doses tend to give all 0s, high doses tend to give all Is, and there is an intermediate range in which doses may give either a 0 or a 1. It is a simple step from this observation to the postulation of an underlying relation of response to dose such that the probability (note that word!) of getting a 1 is low at low doses, high at high doses, and passes smoothly from the first to the second state. In other words, associated with the observed points, we picture a relation such as that given by the curve in the left panel of Figure 2 .
Indeed, we can do better than just postulate such an underlying curve. We can test the idea. This has been done many times, especially with the paradigm quantal response, that underlying LD50 assays. If our postulate is correct, we should be able to give a group of mice one dose, another group a higher dose, and so on until we have covered the doses of interest. If we now plot the fraction of mice responding (or, what is the same, the number of mice responding if we use the same number of mice at each dose level), we should get something like the right panel of Figure 2 . We expect to see the fraction responding as Is to be low at low doses and rise as we pass to higher levels of exposure. Indeed, this is what has been observed countless times in toxicity assays.
Quite often it is possible to give several animals the same dose of drug and therefore to get results of the form of the right panel of Figure 2 and thus end up with a sigmoid curve similar to the more familiar graded assays. However, sometimes it is not possible to get groups of animals all exposed to the same dose. Indeed, many experimental stroke studies are of this nature and the best that can be done is to analyze the results at the level of responses of individual animals. With the advent of modern computers, the fundamental approach of analyzing quantal assays could be automated. 3 When Zivin wanted to analyze his assay results, he simply adopted a program Waud already had available (with some improvements by Robert Lew to make it more user-friendly).t The details of the statistical part of the analysis need not concern us here. However, the general approach is worth outlining. First, since computers cannot deal with vagueness, it was necessary to chose some mathematical function to relate response to dose or, more correctly, probability of response to dose. All we really know is that the function should start at 0, end at 1, and pass smoothly between. Now there is, in general, no a priori basis for choice of this function. For example, at present there is no way we can put together a theoretical model of what happens when we tie off the blood supply to a section of rabbit spinal cord. Indeed, even in the case of graded responses, it is rare to be able to come up with a full quantitative model. Nobody should claim to describe mathematically the factors that determine the shape of the dose-response curve for the action of epinephrine on arterial pressure. Therefore, we have to find some mathematical function that is the right shape and use that as an empirical approximation. There are several candidates available. Classically probits were used, an approach based on the sigmoid nature associated with random errors. 4 Another choice is the arctan function, but it is not used much because it seems to bear no relation to any process of biological interest. A third choice is the so-called logistic function, 5 a relation of the relatively simple form
where R represents the response and D the dose while K and P are measures of ED50 and slope, respectively.:):
The logistic function has a couple of slight advantages that led to its ultimate choice. First, it is much easier for tCopies of a version that runs under PC-or MS-DOS (BASICA or owBASlc, respectively) are available. Send a self-addressed stamped diskette envelope and diskette ($i or 3^ in.) to Zivin. tit is possible to write a logistic function various ways. In the statistical literature it usually is of the form or a variant thereof. However, we prefer the format we use in the text because it is a generalization of the form When D=K, R will be 0.5. That is, the probability of a "hit" will be 0.5. In other words, K amounts to an EDJO. The parameter P is really a fudge factor to enable us to deal with curves with different degrees of steepness^ To see the effect of P, suppose it were 2 instead of 1. The equations tells us that R will then change with the square of D, rather than with its first power; that is, R will change more rapidly with D, so the curve will be steeper.
There is a more interesting aspect to the scale of abscissas in the case of the spinal cord assay. Here we are not dealing with dose in the usual sense since we tie off the circulation for various durations. Thus the dose is really time. Note, however, that we can deal with this exactly the same way we dealt with dose. We simply picture a relation such as that in the left panel of Figure  1 , except that we change the label for the scale of the abscissa from "Dose" to "Time." Conceptually, however, we proceed as usual. We observe mostly 0s at short durations of occlusion, mostly Is at long durations, and a mix in between. In turn, we again view the observations as reflecting an underlying relation of probability §We use the term steepness rather than slope since the latter is not a parameter of the curve but rather varies depending upon where along the curve you look. Some people use the maximal slope, that at the EDJO, as a numerical measure of what we are calling steepness. which is just that logistic equation we presented earlier with the symbols changed to remind us of the system we are dealing with. We write t for time rather than D for duration to emphasize we were not dealing with dose (which inconveniently also begins with the letter d). We also changed the symbol K to ET50 to remind us that the parameter is of the nature of an ED50 (but we swapped the letter D for a T to pay lip service to the replacement of dose by time in our spinal cord assay). The underlying analysis is otherwise that of a standard quantal bioassay.
The details of what the computer does are not important for our purposes here. Suffice it to say that the analysis amounts to giving the computer the results-a series of doses or times (durations of ischemia) with the associated Is or 0s depending on the animal's response -and then telling the computer to find the values of P and K (or ETso) that are most compatible with the experimental observations.
We can also have the computer plot the raw data and, on the same graph, add the curve representing the underlying sigmoid relation of probability of response to dose (or time). Adding this latter frill has been a source of confusion to some people. We suspect that this confusion is usually related to their thinking in terms of the graded case, where the curve and data are closely associated, rather than the quantal case, where there is a step in between.
It may be useful to spell out that intermediate We now try a time of 25 minutes, the probability is 25/(25+25)=0.5. We can continue along these lines until we get something like the curve in the left panel of Figure 2 . It is easier then to think in reverse terms about how a theoretical curve of sigmoid shape could underlie any set of experimental results of the form of the left panel of Figure 1 .
The final advantage of computerized analysis is that error limits are a natural by-product of the computerfitting process. This is particularly advantageous when dealing with comparison of a treatment with control behavior or when comparing two treatments. In both cases we can formulate the problem so that one of the parameters estimated is the potency ratio of interest. In other words, rather than solve for the ET W values of the two curves we can solve for the ET^ of the control curve and a parameter measuring how much greater the ETso of the second curve is. This, of course, is what really interests us -the effect of the treatment, not the actual time associated with the production of pathologic change in rabbits. This rephrasing of the mathematics, coupled with the intrinsic ability of the statistical analysis to yield direct error limits of the estimated parameters, permits us to avoid having to make secondary, indirect estimates of the error limits.
This property of yielding the error limits directly is a convenience that is easy to enjoy. The "why" of it is not easily grasped without a lot of homework. Fortunately, the end user does not have to delve into the details; that is a job for statisticians and the person writing the computer program (Reference 3 gives more details). The user has to supply the program with only the experimental results. The program can be left to work out both the estimates of the parameters and their error limits.
We also note that the ET50 does not represent the behavior of some average rabbit. The ETjo is much better viewed as a parameter describing the behavior of all rabbits in the assay. Statisticians call the ET50 a location parameter; the ET W determines the horizontal location of the curve. If the ETs) is low, the curve lies to the left; if it is high, the curve is shifted to the right. (Statisticians call the parameter P determining steepness a scale parameter because stretching the scale of the abscissa has the effect of altering the steepness of the curve.) We shall return to this idea in the next section, where we shall see drug effects as a change in the location parameter.
Drug Effects
So far we have considered only a single curve. Generally we are interested in two or more. Thus, in the context of stroke we are usually interested not in what the ET50 is for rabbit spinal cord ischemia but rather in whether the ETso can be altered by drugs. Specifically, can the ET50 be made bigger, that is, show a protective or therapeutic effect?
The generalization to this situation is straightforward. Experimentally we look at two groups of rabbits, one without drug and one with. Two sets of doseresponse results are fed into the computer. However, there is a slightly more sophisticated way to do this. We can give the computer both sets at the same time so it can both compare values of the parameter P and, if the values are not significantly different, use a composite value to make maximal use of the information available. Second, instead of having the computer deal with two equations like and Probability 2 = -where we have used the subscripts 1 and 2 to label the control and drug curves, respectively, we use the equation pair What, exactly, is the significance of 5? It is the factor by which the ED*, of the drug curve is larger than that of the control curve (i.e., 5=ED 5 o 2 /ED 5 o | ). In other words, S is what pharmacologists call a potency ratio. For example, if 8 turns out to be 2, then we have found that, with the drug in the picture, ischemia must last twice as long to produce the same degree of neurological deficit. Thus 5 represents the bottom line. We are interested in therapeutic maneuvers that yield as high a positive value for 5 as possible.
While we do not want to go extensively into the details of experimental design, a few comments are in order. Some care is needed in the choice of doses. There should be some doses low enough that a few animals are not affected (e.g., not rendered paraplegic) and some doses high enough that a few animals are affected. Generally one has some a priori knowledge of the behavior of the system being studied to guide the choice of doses. The spacing of doses is also critical. There is a subtle point here. If the spacing is too wide in the midrange, it is possible to end up with results such that all animals below some range of doses are unaffected and all above that range are affected. If this is the case, the ET50 is indeterminate and can have essentially any value in that range of doses. The reason is simply that the computer can fit the observed data by using any one of many pairs of values for the ETso and P parameters. There is no need for the doses in the control and experimental groups to be identical. In fact, this would make no sense at all if the two groups had widely differing values of ETjo. Finally, doses near the ET W give more information about its location than those far removed. Thus, the choice of doses must reflect a IITypically, the data would first be analyzed with a model having both a Pi and a P 2 and the two values would be compared statistically to see if they differ. If not, then the model with the common P becomes appropriate. If, on the other hand, there is evidence of significantly different values for P, then it would be reasonable to be more cautious when looking at changes in ED50 (e.g., a big difference in ED50 might still be of interest, but a more subtle one would be suspect). balance between getting some animals with no response as well as some with a response and having enough doses in the middle to maximize precision. Although this seems complicated, in practice familiarity with the experimental system makes it reasonably easy to carry out.
Examples While an abstract analysis has some advantages of mathematical rigor, an example or two can often give a good feel for what is going on.
For our first example the assay system is the rabbit spinal cord preparation, mentioned earlier. As we increase the duration of ischemia, we increase the probability that the animal will be paralyzed (i.e., the score is 1). The test drug is a glutamate antagonist, MK-801, given at a dose of 1 mg/kg. The experimental results from such a study 6 are presented in Table 1 . Feeding these numbers into the computer gives ED J0i =28.89±1.66 and 5=1.75±0.17 as estimates (mean±SEM) of the parameters.
What do we conclude? The answer is encapsulated in the estimate of the parameter 8. If the drug has no effect, then S should be unity. The actual value estimated is 1.81 with a standard error of 0.25. With 64 animals and three parameters (ED50, S, and P) to be estimated, we have 61 degrees of freedom. A table of t gives 2.0 for a value of p=0.05. This means that we are 95% certain that the true value of S is between 1.75 + (2.0x0.17)=2.09 and 1.75-(2.0x0.17) = 1.41. This interval clearly does not include unity, so we conclude that there is a significant effect. Those of a more functional than statistical bent will focus on the mean value of 5 and note that the drug has increased almost twofold the ability of the organism to withstand the insult inasmuch as, in the presence of the drug, the level of the insult must be increased by that factor to match the control response.
Finally, we can get a visual summary. The estimated values for the parameters can be used to draw the theoretical dose-response relation underlying the experimental values in Table 1 . In the left panel of Figure  3 we have plotted the raw results with the computed curves superimposed. (The use of a logarithmic scale for the time axis is a holdover from analysis of doseresponse curves for which a logarithmic transformation .033
Duration of ischemia (min) Dose of microspheres (milligrams) FIGURE 3. Graphs. is used empirically to spread out the left half of the curve. The logistic function plots symmetrically with a logarithmic scale of the abscissa.) Now let's look at a second example. This time the damage was done by the intracarotid injection of 50-jtm microspheres. Given that it is the microspheres that reach the brain rather than those injected that actually cause the damage, the dose has been expressed in terms of the amount of microspheres trapped in the brain (the microspheres were radiolabeled so it was a straightforward matter to determine the amount of material that ended up in the brain). This refinement of the measure of dose carries with it a complication. It is no longer possible to arrange to have several animals at each dose level because we do not know the dose level until the animal is killed and the brain assayed. However, as already noted, this complication is no problem when the response is viewed in its basic quantal form.
In this experiment, the effect of nimodipine, a calcium channel blocking agent, used at a dose of 5 fig/kg was examined. 7 We list the experimental results in Table 2 .
Feeding the data into the computer yields EDs, = 0.381 ±0.035 and 5=1.264±0.152. This time the 95% confidence interval for 5 includes unity (t is 2.04, and the mean less / times the SEM comes out to be 1.264-[2.04x0.152]=0.95). So this time the intervention did not produce a significant effect.
The right panel of Figure 3 shows the graphical summary.
Other Possible Applications
As promised, we will indicate some ways in which this technique is useful for stroke-related studies. A problem that has plagued physicians is determination of the length of time that cardiac resuscitation attempts should continue. If effective cardiac perfusion is regained rapidly, the patient is more likely to avoid brain damage. However, if the arrest is prolonged, irreversible damage rapidly becomes inevitable, even if a cardiac rhythm is subsequently reestablished. Quantal dose-response analysis can be used to quantify the relation of brain survival to arrest duration. This dose-response relation could then be used as preliminary data for the development of guidelines for deciding the maximum length of resuscitation that might reasonably be expected to be productive. Furthermore, if a new method of adjuncrive therapy becomes available, this type of analysis can be used to objectively quantify the value of the new procedure.
Behavioral measurements in animal studies can be quite labor-intensive. Frequently, the animals must receive some form of training prior to stroke induction, and some of the animals may die because of the surgical procedure before poststroke testing can begin. Typically, the animals must be tested for days before the ability to perform the behavioral task can be confidently assessed. Furthermore, these studies must be done in groups of control and treated animals large enough to determine whether the treatment has an effect. In most models, it is possible to induce graded degrees of damage. This is ordinarily considered a disadvantage because it introduces an additional source of variation. However, to give one example, in global ischemia models it is possible to produce a range of durations of ischemia in a series of animals and observe whether they regain consciousness. Animals that sustain brief periods of ischemia will recover, and animals that are occluded for long periods will all die. The quantal dose-response method can be used to determine the duration of ischemia that produces irreversible damage in each group and can be used to test the effects of therapy in an appropriately matched experimental group. The results from such a study may or may not correlate well with detailed behavioral testing, but it is not evident a priori which type of end point is more valid for predicting the effect of therapy in patients. It is clear that use of the quantal bioassay is much faster than detailed behavioral testing. Similarly, in trauma experiments it is possible to administer a graded amount of energy and use an all-or-none end point to determine the clinical effects. Incidentally, it is not necessary to use death as the only outcome measure. Almost any unequivocal end point that is scientifically meaningful can be used. We can grade the subjects for the presence or absence of paraplegia, coma, hemiparesis, ability to walk across a beam, etc. Also, the end point does not need to be behavioral and, for example, the presence or absence of a morphological finding can be used.
With the quantal data analysis method we have found that it is usually possible to generate a complete doseresponse curve using approximately the same number of subjects required for a t test of results measured on some graded scale such as counting dead neurons in a lesion or measuring lesion size. With the typical graded assay, a single standard insult is employed. For example, we might occlude a vessel for some standard time in a group of animals, measure the index, repeat in another set of animals, and finally compare the two numbers with a t test. In contrast, the quantal assay we describe deals with responses to a range of levels of insult. This generation of a full curve gives several advantages. If duration of ischemia is the independent variable, then generation of the complete curve yields information about the full extent of the ischemia doses rather than a single point. It might seem that measurement of a dichotomous variable would be less sensitive than measurement of a graded response. However, the advantage of an all-or-none choice is that, if chosen properly, it reduces the amount of interobserver and intraobserver variability, which frequently more than compensates for the loss of fine-grain detail.
